Ind-Swift Laboratories Ltd.

NSE: INDSWFTLAB BSE: 532305 SECTOR: Pharmaceuticals & Drugs  7025   15   4

72.60
-0.50 (-0.68%)
NSE: Today, 03:56 PM

Price Summary

Today's High

₹ 73.95

Today's Low

₹ 71.15

52 Week High

₹ 127.45

52 Week Low

₹ 55.15

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

428.97 Cr.

Enterprise Value

1394.32 Cr.

No. of Shares

5.91 Cr.

P/E

17.29

P/B

0.91

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  79.51

CASH

9.95 Cr.

DEBT

975.3 Cr.

Promoter Holding

42 %

EPS (TTM)

₹  4.2

Sales Growth

13.93%

ROE

-1.04 %

ROCE

8.24%

Profit Growth

78.84 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year13.93%
3 Year5.56%
5 Year6.04%

Profit Growth

1 Year78.84%
3 Year-162.96%
5 Year14%

ROE%

1 Year-1.04%
3 Year1.89%
5 Year-0.85%

ROCE %

1 Year8.24%
3 Year8.31%
5 Year6.3%

Debt/Equity

2.2791

Price to Cash Flow

3.18

Interest Cover Ratio

1.16085058563342

CFO/PAT (5 Yr. Avg.)

0

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2021 42 86.87
Jun 2021 42 86.87
Mar 2021 42 86.87
Dec 2020 42 86.87
Sep 2020 42 86.87
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company has a healthy liquidity position with current ratio of 3.01974051575276.

 Limitations

  • The company has shown a poor profit growth of -162.958738058471% for the Past 3 years.
  • The company has shown a poor revenue growth of 5.55524517323251% for the Past 3 years.
  • Company has a poor ROE of 1.88895008556979% over the past 3 years.
  • Promoter pledging has increased from 42% to 86.87% in 1 quarter.
  • Promoter pledging is high as 86.87%.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021
Net Sales 221.2 213.68 217.84 242.05 229.92
Total Expenditure 172.97 165.57 176.66 190.99 175.15
Operating Profit 48.23 48.12 41.18 51.06 54.77
Other Income 5.79 8.84 2.56 5.95 7.15
Interest 24.96 25.91 24.31 24.12 24.19
Depreciation 19.85 19.83 27.93 14.06 13.87
Exceptional Items 0 0 0 0 0
Profit Before Tax 9.22 11.22 -8.5 18.83 23.85
Tax 0 0 20.52 0.08 0
Profit After Tax 9.22 11.22 -29.02 18.75 23.85
Adjusted EPS (Rs) 1.56 1.9 -4.91 3.17 4.04

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Net Sales 674.9 728.33 724.43 751.84 856.58
Total Expenditure 569.87 601.53 599.15 610.78 676.1
Operating Profit 105.04 126.8 125.28 141.06 180.48
Other Income 22.62 25.7 47 36.08 23.13
Interest 90.25 35.36 92.24 106.65 100.2
Depreciation 88.26 86.62 104.05 90.06 87.29
Exceptional Items -5.34 -1.94 82.94 0 0
Profit Before Tax -56.19 28.58 58.93 -19.56 16.12
Tax -16.46 10.96 20.35 1.23 20.52
Net Profit -39.73 17.62 38.58 -20.79 -4.4
Adjusted EPS (Rs.) -8.88 3.89 8.11 -3.52 -0.74

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Equity and Liabilities
Share Capital 45.46 46 48.29 59.81 59.81
Total Reserves 480.42 497.38 542 584.8 578.89
Borrowings 592.01 520.5 965.58 890.89 875.41
Other N/C liabilities -97.25 -82.69 -64.26 -62.56 -42.46
Current liabilities 994.23 919.84 342.34 309.29 286.71
Total Liabilities 2014.88 1901.02 1833.96 1782.23 1758.36
Assets
Net Block 1032.35 924.38 900.99 842.93 752.41
Capital WIP 61.48 61.74 12.62 3.8 10.7
Intangible WIP 8.79 6.87 7.26 7.65 8.14
Investments 39.35 39.12 38.88 26.36 55.33
Loans & Advances 54.21 63.48 56.92 56.92 65.97
Other N/C Assets 14.31 0 0 0 0
Current Assets 804.41 805.44 817.29 844.56 865.8
Total Assets 2014.88 1901.02 1833.96 1782.23 1758.36
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Profit from operations -50.85 30.52 -24.01 -19.56 16.12
Adjustment 167.95 103.64 176.17 176.02 179.35
Changes in Assets & Liabilities -24.43 -62.7 -226.79 -33.3 -60.43
Tax Paid 0 0 0 0 0
Operating Cash Flow 92.67 71.46 -74.63 123.16 135.03
Investing Cash Flow -30.99 -17.25 -2.34 -10.15 -10.17
Financing Cash Flow -68.9 -61.98 99.62 -133.26 -123.75
Net Cash Flow -7.22 -7.78 22.66 -20.25 1.11

Corporate Actions

Investors Details

PARTICULARS Sep 2020% Dec 2020% Mar 2021% Jun 2021% Sep 2021%
Promoters 42.00 42.00 42.00 42.00 42.00
essix biosciences ... 21.71 21.71 21.71 21.71 21.71
ind swift ltd 16.08 16.08 16.08 16.08 16.08
n.r munjal 1.56 1.56 1.56 1.56 1.56
rishav mehta 0.77 0.77 0.77 0.77 0.77
himanshu jain 0.69 0.69 0.69 0.69 0.69
neera mehta 0.42 0.42 0.42 0.42 0.42
s.r mehta 0.40 0.40 0.40 0.40 0.40
gopal munjal 0.10 0.10 0.10 0.10 0.10
v.r mehta 0.09 0.09 0.09 0.09 0.09
sunita jain 0.08 0.08 0.08 0.08 0.08
meenakshi mehta 0.02 0.02 0.02 0.02 0.02
neeta munjal 0.02 0.02 0.02 0.02 0.02
nidhi munjal 0.02 0.02 0.02 0.02 0.02
ravi mehta 0.02 0.02 0.02 0.02 0.02
bhanavi mehta 0.01 0.01 0.01 0.01 0.01
divya munjal 0.01 0.01 0.01 0.01 0.01
ishav mehta 0.01 0.01 0.01 0.01 0.01
PARTICULARS Sep 2020% Dec 2020% Mar 2021% Jun 2021% Sep 2021%
Investors 58.00 58.00 58.00 58.00 58.00
edelweiss india sp... 10.43 10.43 10.43 10.43 10.43
ec special situati... 6.82 6.82 6.82 6.82 6.82
ashokkumar chandak 3.45 3.58 3.19 2.79 3.12
eisaf ii onshore f... 2.24 2.24 2.24 2.24 2.24
gryffin advisory s... - - - - -
bsas infotech ltd 1.72 1.43 - - -
sri ganesh biotech... 1.18 1.18 1.21 1.26 1.30
conquer investment... 1.12 1.12 1.18 1.18 1.18
edelweiss asset re... - - - - -
iepf 0.26 0.26 0.26 0.26 0.26

Annual Reports

Ratings & Research Reports

Company Presentations

  • PresentationQ2FY21 20 Nov 2020

Ind-Swift Lab. Stock Price Analysis and Quick Research Report. Is Ind-Swift Lab. an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Ind-Swift Lab. and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 135.0317 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Ind-Swift Lab. has a Debt to Equity ratio of 2.2791 , which is a weak indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Ind-Swift Lab. , the EPS growth was 78.840851596032 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Ind-Swift Lab. has OPM of 21.0698985638676 % which is a good sign for profitability.
     
  • ROE: Ind-Swift Lab. have a poor ROE of -1.03973942569307 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Ind-Swift Lab.

X